2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CLINICAL CANCER RESEARCH CLIN CANCER RES (此期刊被最新的JCR期刊SCIE收录) LetPub评分 9.3
51人评分
我要评分
声誉 9.9 影响力 8.7 速度 9.6 | |||||||||||||||||||||
期刊ISSN | 1078-0432 | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 1557-3265 | |||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 10 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2024年3月26日:10.062 | |||||||||||||||||||||
2023-2024自引率 | 2.00%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 11.1 | |||||||||||||||||||||
JCI期刊引文指标 | 2.57 | |||||||||||||||||||||
h-index | 292 | |||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | http://clincancerres.aacrjournals.org/ | |||||||||||||||||||||
期刊投稿网址 | http://ccr.msubmit.net/cgi-bin/main.plex | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CLINICAL CANCER RESEARCH的语言要求,还能让CLINICAL CANCER RESEARCH编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CLINICAL CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404 | |||||||||||||||||||||
出版商 | American Association for Cancer Research Inc. | |||||||||||||||||||||
涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Semimonthly | |||||||||||||||||||||
出版年份 | 1995 | |||||||||||||||||||||
年文章数 | 467点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 30.05% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 92.93% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:1区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月升级版) |
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2021年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1078-0432%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均2.1月 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: 约30% | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在CLINICAL CANCER RESEARCH顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
中国学者近期发表的论文 | |
1. | Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy Author: Chen, Wei; Shi, Hui; Liu, Zhuojun; Yang, Fan; Liu, Jia; Zhang, Leqiang; Wu, Yajin; Xia, Yuanshi; Ou, Yuxuan; Li, Ruiting; Zhang, Ting; Zhang, Jiecheng; Ke, Xiaoyan; Hu, Kai; Yu, Jian Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 8, pp. 1484-1495. DOI: 10.1158/1078-0432.CCR-22-2924 PubMed DOI |
2. | Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies Author: Zhai, Yifan; Tang, Qiuqiong; Fang, Douglas D.; Deng, Jing; Zhang, Kaixiang; Wang, Qixin; Yin, Yan; Fu, Chengcheng; Xue, Sheng -Li; Li, Na; Zhou, Feng; Yang, Dajun Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 183-196. DOI: 10.1158/1078-0432.CCR-22-0978 PubMed DOI |
3. | Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer Author: Peng, Ke; Zhang, Feifei; Wang, Yichen; Sahgal, Pranshu; Li, Tianxia; Zhou, Jin; Liang, Xiaoyan; Zhang, Yanxi; Sethi, Nilay; Liu, Tianshu; Zhang, Haisheng; Bass, Adam J. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 197-208. DOI: 10.1158/1078-0432.CCR-22-1609 PubMed DOI |
4. | Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes Author: Bai, Jiwei; Shi, Jianxin; Zhang, Yazhuo; Li, Chuzhong; Xiong, Yujia; Koka, Hela; Wang, Difei; Zhang, Tongwu; Song, Lei; Luo, Wen; Zhu, Bin; Hicks, Belynda; Hutchinson, Amy; Kirk, Erin; Troester, Melissa A.; Li, Mingxuan; Shen, Yutao; Ma, Tianshun; Wang, Junmei; Liu, Xing; Wang, Shuai; Gui, Songbai; McMaster, Mary L.; Chanock, Stephen J.; Parry, Dilys M.; Goldstein, Alisa M.; Yang, Xiaohong R. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 261-270. DOI: 10.1158/1078-0432.CCR-22-1865 PubMed DOI |
5. | Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma Author: Wang, Jun; Guo, Wei; Wang, Xiaofang; Tang, Xiaodong; Sun, Xin; Ren, Tingting Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 659-666. DOI: 10.1158/1078-0432.CCR-22-2682 PubMed DOI |
6. | Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect Author: Luo, Ren; Onyshchenko, Kateryna; Wang, Liqun; Gaedicke, Simone; Grosu, Anca-Ligia; Firat, Elke; Niedermann, Gabriele Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 667-683. DOI: 10.1158/1078-0432.CCR-22-1591 PubMed DOI |
7. | First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001 Author: Zhou, Yan; Yang, Qingcheng; Dong, Yang; Ji, Tong; Zhang, Bing; Yang, Cheng; Zheng, Shuier; Tang, Lina; Zhou, Chenliang; Qian, Guowei; Huang, Yujing; Yu, Wenxi; Li, Hongtao; Wang, Yonggang; He, Aina; Shen, Zan; Bao, Qiyuan; Hua, Yingqi; Bai, Hongyu; Zhao, Jiayi; Li, Xiaoyi; Dai, Xiangrong; Zhang, Jianjun; Hu, Haiyan; Yao, Yang Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 764-774. DOI: 10.1158/1078-0432.CCR-22-2470 PubMed DOI |
8. | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma Author: Song, Xuyang; Kelley, Robin Kate; Khan, Anis A.; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F.; Abou-Alfa, Ghassan K. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 754-763. DOI: 10.1158/1078-0432.CCR-22-1983 PubMed DOI |
9. | Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer Author: Chen, Huang; Zhou, Wenbo; Bian, Aiwu; Zhang, Qiansen; Miao, Ying; Yin, Xuan; Ye, Jiangnan; Xu, Shifen; Ti, Chaowen; Sun, Zhenliang; Zheng, Jianghua; Chen, Yihua; Liu, Mingyao; Yi, Zhengfang Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 815-830. DOI: 10.1158/1078-0432.CCR-22-0997 PubMed DOI |
10. | An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas Author: Lu, Xiaofan; Vano, Yann; Helleux, Alexandra; Su, Xiaoping; Lindner, Veronique; Davidson, Guillaume; Mouawad, Roger; Spano, Jean-Philippe; Roupre, Morgan; Elaidi, Reza; Comperat, Eva; Verkarre, Virginie; Sun, Chengming; Chevreau, Christine; Bennamoun, Mostefa; Lang, Herve; Tricard, Thibault; Cheng, Wenxuan; Xu, Li; Davidson, Irwin; Yan, Fangrong; Fridman, Wolf Herman; Sautes-Fridman, Catherine; Oudard, Stephane; Malouf, Gabriel G. Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 7, pp. 1279-1291. DOI: 10.1158/1078-0432.CCR-22-2133 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室